<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
x

Optimizing Inhibitors for RET Rearranged Tumors

The targeted inhibition of oncogenic driver mutations is an underlying principle of oncology precision medicine. Rearrangements of the RET gene have been found in a range of cancers (e.g. lung adenocarcinoma, CRC), providing a potentially druggable target.